Intravenous Administration of PRP in Neurological Disorders

Intravenous Administration of PRP in Neurological Disorders

Intravenous (IV) Platelet Rich Plasma (PRP) is a concentration of platelets that are prepared and injected into a vein. Intravenous PRP is being investigated to address neurological disorders, as well as to help in other areas like memory. Neurological disorders include conditions like Parkinson's disease.

Continue reading to see how PRP and neurology meet, what is used in the intravenous PRP preparation process, and the possible side effect you may experience.

Why Consider Intravenous PRP?

Unlike a local injection, delivering PRP therapy intravenously may allow for the PRP to travel to the body area in need of healing, rather than the healing being isolated to a specific area.

With a more systemic healing effect, IV PRP may help to call upon the patient’s stem cells to aid tissue regeneration and create the environment necessary for the PRP to function properly. Intravenous PRP may be able to regenerate the central nervous system.

Preparing Intravenous PRP and Risk of Clotting

IV PRP can be prepared with TruDose PRP to calculate the exact amount of blood needed to prepare a “therapeutic” dose and treat conditions like Parkinson’s disease.

TruDose PRP does not appear to raise the chance of clotting (there is a chance that platelets can suddenly clot when they enter the bloodstream).

Applicant's Harbour Cell Software™ can also be used, as it determines exact blood aspiration volume to prepare a PRP dose with a minimum 2.0×106 platelets/μL to address neurological disorders. When IV surpraphysiologic PRP was given to nine patients, all seemed to benefit, reporting improvements in areas like neurocognition, memory, and handwriting. When two patients received localized injections, they reported pain relief from injury and nothing else.

In regards to blood clotting, non-pediatric patients with an autoimmune, auto-inflammatory, and chronic diseases achieved effects with IV PRP that exceed 3.0×106 platelets/μL without dilution with anticoagulants or saline.